VDAC2の喪失は,がん治療のための腫瘍破壊と炎症を引き起こします.
PubMedで要約を見る
まとめ
この要約は機械生成です。腫瘍細胞は,電圧依存アニオンチャネル2 (VDAC2) を含むメカニズムによって免疫攻撃を回避する. VDAC2をターゲットにすることで,インターフェロン・ガンマ (IFNγ) が細胞死と先天的な免疫反応を誘発することで,抗腫瘍免疫と免疫療法の有効性を高めます.
科学分野
- 免疫学
- 分子生物学
- 癌 研究
背景
- 腫瘍細胞はしばしば免疫監視や治療介入を回避し,その背後にあるメカニズムはほとんど不明である.
- CD8+ T細胞と免疫療法に対する耐性は,がん治療において重要な課題となっています.
- 腫瘍の免疫回避を理解することは 効果的ながん治療法の開発に不可欠です
研究 の 目的
- 腫瘍の免疫回避を媒介する 新しい分子標的を特定するためです
- 免疫攻撃に対する腫瘍抵抗における代謝因子の役割を調査する.
- VDAC2を抗腫瘍免疫と免疫療法の潜在的な標的として調査する.
主な方法
- 代謝因子を標的とした生体内および体内CRISPR-Cas9遺伝子スクリーニング.
- 相互作用する遺伝子を特定するためのゲノムスケールの遺伝子相互作用スクリーンです.
- インターフェロン-ガンマ (IFNγ) シグナル伝達経路とミトコンドリア損傷の分析
- cGAS-STINGの活性化とタイプIのIFN応答の評価
主要な成果
- 電圧依存アニオンチャネル2 (VDAC2) は,IFNγ媒介による腫瘍破壊を制限する免疫信号依存チェックポイントとして特定されました.
- 腫瘍細胞におけるVDAC2を標的にすることで,IFNγ誘発細胞死,cGAS- STING活性化,および抗腫瘍反応が強化された.
- BAKはVDAC2欠乏による作用の主要な媒介体として特定され,制御不能なBAK活性化とミトコンドリア損傷につながった.
- ミトコンドリアDNAの異常放出は,cGAS- STINGシグナル伝達と1型IFN応答を誘発し,抗腫瘍免疫を強化した.
結論
- VDAC2は,適応的および先天的な免疫反応の両方を強化することによって,腫瘍の免疫回避を克服する重要な標的です.
- VDAC2をターゲットにすることで,腫瘍細胞の死と炎症が促進され,がん免疫療法の有効性が向上します.
- 癌の免疫療法の成功には 組織的な腫瘍破壊と炎症が不可欠です
関連する概念動画
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

